Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533117 · ClinicalTrials.gov registry record · Phase 4
Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT00533117 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 91 participants.
The verdict
NCT00533117, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.
Interventions
- BEHAVIORAL Dialectical Behavior Therapy
- DRUG Fluoxetine
- BEHAVIORAL Supportive psychotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2001-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533117
The ClinicalTrials.gov registry entry for NCT00533117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dialectical Behavior Therapy is the first listed.
NCT00533117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533117 about?
NCT00533117 is a clinical study titled "Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder". This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.
What is the current status of trial NCT00533117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2001-03. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00533117?
The interventions under investigation include: Dialectical Behavior Therapy (BEHAVIORAL), Fluoxetine (DRUG), Supportive psychotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00533117?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.